You probably know someone who dreads the yearly mammogram.
For millions of women, the scan is the main line of defense against breast cancer. But the picture is not always clear, and sometimes a tumor hides in dense tissue.
An experimental blood test developed in Israel spotted early breast cancer with 95 percent accuracy and flagged which patients were more likely to see the disease return.
The findings were published in the journal Nature in November 2026.
Also read: She monitored her blood sugar for 30 days: Here's what surprised her
Behind the work are Prof. Efrat Shema of the Weizmann Institute of Science and Prof. Guy Ron of the Hebrew University of Jerusalem.
They worked with doctors at Kaplan Medical Center and the Sheba Medical Center.
The team tested samples from 77 women with breast cancer and 30 healthy women.
The results were then checked against a larger set of 188 patient samples.
Also read: How eating eggs five times a week may lower your Alzheimer's risk
How the blood test looks for signs of cancer
When cells die, they release tiny DNA packages called nucleosomes into the bloodstream.
Cancer cells leave their own distinct chemical marks on these packages.
The researchers used fluorescent labels and powerful microscopes to read those marks from less than a milliliter of plasma.
The signals were then run through software that looks for patterns linked to a tumor.
Also read: Research reveals how to build muscle more effectively after 40
The test picked up tumors that were still confined to the breast and measured no more than 2 centimeters across, according to the press release on EurekAlert!.
It worked across different cancer types and across patients with denser breast tissue.
"Breast cancer screening saves lives,” Shema says according to EurekAlert!. “Regular mammograms reduce the risk of dying from the disease by 22 percent, but the denser the breast tissue, the easier it is for a tumor to ‘hide’ in the image
Dense breast tissue is already linked to higher breast cancer risk and makes screening harder.
Also read: These sleep mistakes could be affecting your mood
Predicting whose cancer may come back
The researchers then turned to the harder question of recurrence.
In the larger sample set, the blood test distinguished women whose cancer later returned from those who stayed well with 81 percent accuracy.
Ron told EurekAlert! that the team found small groups of highly aggressive cells hiding inside tumors that otherwise looked mild.
The more clearly their chemical fingerprint showed up in a blood sample, the greater the risk that the disease would come back, he said.
Also read: Eating less protein could help you age more slowly, study suggests
The test even flagged risk in patients who had been labeled low risk by standard tissue biopsy.
That could change how doctors decide who needs closer follow-up after treatment.
Still experimental and not available in the clinic
The test is not yet standard of care. The study is a proof of concept, and larger trials and regulatory review will have to come before any hospital or screening program can use it.
For now, mammography remains the backbone of breast cancer screening.
The American Cancer Society estimates that 321,910 American women will be diagnosed with invasive breast cancer in 2026, and 42,140 women will die from the disease.
Women with symptoms, dense breasts or a strong family history should talk to their doctor about which screening schedule fits them.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.
